Praxis Precision Medicines (PRAX)
(Real Time Quote from BATS)
$73.05 USD
+1.00 (1.39%)
Updated Oct 16, 2024 03:20 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Income Statements
Fiscal Year end for Praxis Precision Medicines, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 2 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 129 | 215 | 167 | 62 | 36 |
Income After Depreciation & Amortization | -126 | -215 | -167 | -62 | -36 |
Non-Operating Income | 3 | 1 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -123 | -214 | -167 | -62 | -36 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -123 | -214 | -167 | -62 | -36 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -123 | -214 | -167 | -62 | -36 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -126 | -214 | -165 | -62 | -36 |
Depreciation & Amortization (Cash Flow) | 0 | 1 | 2 | 0 | 0 |
Income After Depreciation & Amortization | -126 | -215 | -167 | -62 | -36 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 6.59 | 3.08 | 2.83 | 0.60 | NA |
Diluted EPS Before Non-Recurring Items | -18.69 | -69.57 | -59.07 | -117.84 | NA |
Diluted Net EPS (GAAP) | -18.69 | -69.57 | -59.07 | -117.84 | -398.80 |
Fiscal Year end for Praxis Precision Medicines, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.36 | 0.43 | 0.52 | 0.47 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.36 | 0.43 | 0.52 | 0.47 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 37.85 | 42.31 | 28.32 | 25.98 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -37.49 | -41.88 | -27.80 | -25.51 |
Non-Operating Income | NA | 4.81 | 2.33 | 0.93 | 0.88 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -32.68 | -39.55 | -26.88 | -24.63 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -32.68 | -39.55 | -26.88 | -24.63 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -32.68 | -39.55 | -26.88 | -24.63 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 18.83 | 13.90 | 9.06 | 9.04 |
Diluted EPS Before Non-Recurring Items | NA | -1.74 | -2.84 | -2.97 | -2.70 |
Diluted Net EPS (GAAP) | NA | -1.74 | -2.84 | 2.00 | -2.70 |